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$141,220/QALY versus orchiectomy. Changes in key
variables in the sensitivity analyses did not affect the
ranking of the treatment strategies, suggesting that the
model was robust. 
CONCLUSIONS: LAs were dominated by orchiectomy
in the base case analysis and most sensitivity analyses.
Combination therapy displayed incremental cost 
effectiveness ratios over orchiectomy ranging from
approximately $30,000 to over $100,000 per QALY.
Orchiectomy was more effective, had fewer severe
adverse reactions, and cost slightly more than DES, the
least expensive treatment. However, due to potential 
psychological impact, further research is warranted to
examine its acceptance by patients. Despite robustness,
the utilities used in the model warrant further research.
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OBJECTIVE: This study aimed to 1) assess and compare
the preferences and utilities for prostate cancer (PC)
health states from men at increased risk for disease to
published reports of healthy men, men with PC, and
physician preferences/utilities, and 2) evaluate the theo-
retical congruence of utility values solicited from an 
at-risk population with the conceptual framework for
utility elicitation, Welfare Economics. Several cost-utility
studies have shown little beneﬁt for the cost of screening
or treatment of asymptomatic PC. However, subjects
from whom utilities were elicited in these studies were not
those who would be most affected by health policy 
decisions. Further, several reports assessed utilities from
subjects who violate certain tenets (e.g., Veil of Ignorance)
of Welfare Economics. 
METHODS: 81 men without PC but at increased risk 
for disease (deﬁned by age, ethnicity and family history),
participating in a PC Risk Assessment Program, were
interviewed using the Time Trade-Off Technique. Men’s
preferences and utilities for health states of impotence and
incontinence associated with treatment options of PC
were assessed. 
RESULTS: Utility values ranged from a high of 0.8859
(SD 0.2317) for a small (10%) risk of incontinence 
associated with radiotherapy to a low of 0.7571 (SD
0.2802) for a high (99%) risk of impotence associated
with hormones. As compared to previous reports of
healthy men and physicians, men at-risk for PC in this
study had a higher utility for therapies that have a higher
probability of preserving quality of life, but not as high
as men diagnosed with PC. 
CONCLUSION: Men at-risk for PC had utilities values
for health states associated with treatment options 
intermediate between healthy men and men with cancer,
supporting our hypothesis. We discuss why populations
at-risk may theoretically be more congruent with Welfare
Economics and the Veil of Ignorance concept than 
populations previously reported in the literature.
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OBJECTIVE: To determine if cancer treatment choices
differ for prostate cancer patients who have had other
prior cancers versus those with no history of cancer. 
METHODS: Study was conducted using IMS HEALTH’s
LifeLink database, a U.S. employer claims database con-
sisting of more than 1.8 million covered lives, with linked
medical and pharmacy claims for employees, dependents,
and retirees from 1991 forward. Patients selected for the
study were newly diagnosed with primary prostate cancer
between during 1996–1997 and had at least one claim for
a therapy of interest (drug, surgery, or radiation) follow-
ing their cancer diagnosis. Differentiation of prostate
cancer patients with prior cancers and those without was
based on the documentation of any cancer diagnoses 
in the 36 months preceding their initial prostate cancer
diagnosis. Patients were observed for 36 months after
their diagnosis. 
RESULTS: 5,569 patients met the inclusion criteria of
which 2,811 had a history of prior cancer diagnoses, and
2,758 had no history of prior cancers. Prostate cancer
patients with prior cancers were signiﬁcantly more likely
to receive chemotherapy than patients without prior
cancers (p = 0.015) but were less likely to receive surgery
than patients without prior cancers (p = 0.011). Among
patients treated with chemotherapy, those with prior
cancers were more likely to receive ﬂuorouracil (p =
0.001), whereas patients with no prior cancers were more
likely to receive methotrexate (p = 0.002). Initial treat-
ment modalities also differed signiﬁcantly (p < 0.001),
with prior cancer patients more likely to initially receive
chemotherapy than patients without prior cancers 
(p < 0.001) and signiﬁcant differences in initial hormonal
therapies prescribed (p = 0.024). Among patients with
initial hormone therapy, those with prior cancers were
more likely to initially receive dexamethasone (p < 0.001). 
CONCLUSIONS: Treatment of prostate cancer differs
based on patient’s history of other cancers, both in type
of treatment received (drug, surgery, or radiation) and
selection of hormonal and chemotherapy regimens.
